Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
107
Views
21
CrossRef citations to date
0
Altmetric
Original Research

The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer

Zhiyao Fan1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Kun Fan1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Yitao Gong1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Qiuyi Huang1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Chao Yang1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
He Cheng1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Kaizhou Jin1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Quanxing Ni1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China
,
Xianjun Yu1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-6697-7143
ORCID Icon,
Guopei Luo1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected] [email protected]
&
Chen Liu1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China;4 Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0001-8155-773X
ORCID Icon show all
Pages 8781-8788 | Published online: 30 Sep 2019
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Purpose

The CRP/albumin (Alb) ratio, a recently reported predictor, has shown value for prognosis in various human cancers. This study aimed to determine the prognostic value of baseline CRP/Alb and to explore the relevance between postchemotherapy CRP/Alb and the efficacy of chemotherapy in advanced pancreatic cancer patients.

Patients and methods

Five hundred and ninety-five patients diagnosed with locally advanced or metastatic adenocarcinoma of the pancreas were enrolled. Cut-off Finder was used to calculate the best cut‑off value for baseline CRP/Alb. The primary endpoint was overall survival, which was analyzed by Kaplan-Meier survival curves with 95% confidence intervals. The log rank test and Cox proportional hazard model were used to evaluate the univariate and multivariate analyses.

Results

The optimal cut-off value for baseline CRP/Alb was determined to be 0.18. Both the baseline CRP/Alb (CRP/Alb≥0.18 vs. CRP/Alb<0.18, hazard ratio [HR] = 2.506; p<0.001) and postchemotherapy CRP/Alb (CRP/Alb≥0.18 vs. CRP/Alb<0.18, HR = 1.854; p =0.002) were significant predictors of overall survival according to multivariate analysis and were independent of other factors. Patients with a baseline and postchemotherapy CRP/Alb ≥0.18 had the worst prognosis.

Conclusion

CRP/Alb is a strong and useful indicator of prognosis for advanced pancreatic cancer. Both baseline and postchemotherapy CRP/Alb can be used in predicting the survival of patients and monitoring the effectiveness of chemotherapy in clinical practice.

Funding

This work was supported by The National Science Fund for Distinguished Young Scholars (grant number 81625016).

Disclosure

The authors report no conflicts of interest in this work.

Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.